SIRT1 represents a mechanistically validated target with notable progress in early-stage drug development for MASLD. With further in-depth analysis of its regulatory network and continued optimization ...
HO-1 inhibits the activation of the TGF-ß/Smad3 pathway in NAFLD-related liver fibrosis through SIRT1. These findings provide insights into new therapeutic strategies for treating NAFLD-associated ...
Heme oxygenase 1 (HO-1) has an influential yet insufficiently investigated effect on Sirtuin 1 (SIRT1), a histone deacetylase activated by nicotinamide adenine dinucleotide, which may impact the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results